PT Industri Jamu Sido Muncul stock (ID1000126402): Q1 2026 net profit falls to Rp 147.2B

PT Industri Jamu Sido Muncul Tbk (SIDO) reported Q1 2026 net profit of Rp 147.2 billion, down from prior year, with revenue dropping 19% to Rp 640.5 billion amid softer sales.

PT Industri Jamu Sido Muncul Tbk (SIDO), Indonesia's leading herbal medicine producer, released its Q1 2026 financial results showing a decline in performance. Net profit fell to Rp 147.2 billion from the previous year, while revenue decreased 19% to Rp 640.5 billion, according to Indo Premier Sekuritas as of May 2026 and Babel Insight as of May 2026. The company remains optimistic about the herbal sector's growth.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: PT Industri Jamu dan Farmasi Sido Muncul Tbk
• Sector/industry: Herbal medicine and pharmaceuticals
• Headquarters/country: Indonesia
• Core markets: Indonesia
• Key revenue drivers: Branded herbal products like Tolak Angin
• Home exchange/listing venue: Indonesia Stock Exchange (IDX: SIDO)
• Trading currency: IDR

PT Industri Jamu Sido Muncul: core business model

PT Industri Jamu Sido Muncul Tbk specializes in traditional Indonesian herbal medicines, known as jamu, produced with modern machinery. Founded in 1940 in Yogyakarta as a home industry, it has grown into a market leader, according to Wikipedia. The company focuses on branded products targeting common ailments.

Its flagship brand, Tolak Angin, dominates the herbal remedy market for colds and flu. Sido Muncul operates retail distribution across Indonesia and exports select products, emphasizing natural ingredients compliant with local regulations.

Main revenue and product drivers for PT Industri Jamu Sido Muncul

Revenue primarily comes from over-the-counter herbal supplements and tonics. In Q1 2026, sales fell 19% year-over-year to Rp 640.5 billion due to weaker demand, as reported by Babel Insight as of May 2026. Net profit declined to Rp 147.2 billion for the quarter ending March 31, 2026, per Indo Premier as of May 2026.

Key products include Tolak Angin variants, which account for a significant portion of sales. The company invests in production efficiency and marketing to maintain its top position in Indonesia's jamu sector.

Industry trends and competitive position

Indonesia's herbal medicine market benefits from growing consumer preference for natural remedies. Sido Muncul holds a dominant share, as noted in Warta Jogja as of May 2026, targeting Rp 1.2 trillion in annual profit amid sector expansion.

Competitors include other jamu producers, but Sido Muncul's brand strength and distribution network provide a competitive edge. The firm sees sustained demand for herbal fever remedies into 2026, per YouTube analysis as of May 2026.

Why PT Industri Jamu Sido Muncul matters for US investors

US investors may track Sido Muncul for exposure to Southeast Asia's consumer health sector, particularly Indonesia's emerging middle class driving herbal product demand. Listed on the Indonesia Stock Exchange (IDX: SIDO), it offers diversification into non-US markets with stable currency in IDR.

Recent stock price around 476 IDR as of May 2026 on IDX reflects market reactions to Q1 results, per company IR as of May 2026. Global interest in natural wellness ties into US trends.

Conclusion

PT Industri Jamu Sido Muncul reported softer Q1 2026 results with revenue down 19% and net profit at Rp 147.2 billion, reflecting sales challenges. Despite this, the company eyes herbal market growth and maintains market leadership. Investors monitor upcoming quarters for recovery signs in Indonesia's wellness sector.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.